Psychotic disorders are serious brain-based conditions affecting nearly 3 million adults in the United States. They often require complex, longitudinal care—spanning medication management, psychotherapy, care coordination, and family support—that is difficult to deliver consistently in general practice.

Over the past decades, the field has developed effective, evidence-based approaches that improve meaningful outcomes, including symptom control, recovery, and functional rehabilitation. The challenge is not a lack of knowledge—it is a gap in how that care is delivered.

Highly effective treatments such as clozapine, long-acting injectable antipsychotics, and lithium remain significantly underutilized, often due to the expertise, monitoring, and infrastructure they require. At the same time, treatment can drift toward polypharmacy, increasing side effect burden without clear evidence of benefit. Newer treatments may also be underused due to limited familiarity.

Clinical care is further limited by a lack of structured measurement. Symptoms, functioning, and side effects are not always tracked systematically, and treatment decisions may rely more on impressions than on longitudinal data. This makes it difficult to clearly assess progress, optimize care, or identify early signs of relapse.

Engagement presents an additional challenge. Treatment decisions may not always align with patients’ goals and lived experience, and side effects may go under-recognized or insufficiently addressed, contributing to disengagement over time. Families and supports are often left to navigate a fragmented system with limited guidance.

Access to specialized care remains geographically constrained, and coordination across providers is often inconsistent. As a result, many individuals do not receive the level of care required for optimal outcomes.

These challenges are well established—and for many individuals and families, deeply familiar.

Models such as Coordinated Specialty Care (CSC) were developed to address these gaps through integrated, evidence-based treatment. However, access to this level of care can be limited by geography or by the stage of illness.